Is Geneuro SA halal to invest in?

According to Musaffa's Shariah screening methodology, Geneuro SA (GNRO.PA) is currently classified as NOT HALAL as of September 2024. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Geneuro SA a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Geneuro SA using these criteria to determine its compliance status.

Can Muslims buy shares of Geneuro SA?

Muslim investors may consider investing in Geneuro SA if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Geneuro SA classified as NOT HALAL?

Musaffa determines the Shariah status of Geneuro SA by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Geneuro SA updated?

The Shariah compliance status of Geneuro SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Geneuro SA become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Geneuro SA?

You can check the latest Shariah compliance status of Geneuro SA on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Geneuro SA GNRO.PA

€0.03 €0.00 (0.65%) 1D

Last Updated: Jan 22, 12:00 AM·XPAR

GNRO.PA Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: September 12, 2024

Report Source: 2023 Annual Report

Analyst's Ratings for Geneuro SA (GNRO.PA)

Based on 7 analysts giving stock ratings to Geneuro SA in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Geneuro SA. Stock Analysis GNRO.PA

France Health Care Nano Cap Report: 2023 Annual

GeNeuro SA engages in the research and development of treatments against neurological disorders and autoimmune disease. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 19 full-time employees. The company went IPO on 2016-04-15. The firm's main product, GNbAC1, is a humanized monoclonal antibody that is in clinical development phase IIb. GNbAC1 neutralizes the MSRV-Env protein rather than targeting the patient's immune system, and slows down or even halts the progression of multiple sclerosis. The firm's main shareholders are Eclosion2, a launching platform for new companies in the life sciences field, bioMerieux SA, which specializes in vitro diagnostics for medical and industrial applications, Institut Merieux, a private equity company, and Servier, an independent French pharmaceutical company.

Key Statistics of Geneuro SA (GNRO.PA)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

€0.03€0.03

Today's Open

€0.03

Volume

67.72K

P/E Ratio (TTM)

52 Week Range

€0.02€0.12

Market Cap

910.00K

Avg. Volume

51.18K

Dividend Yield

Financial Metrics & Statements of Geneuro SA (GNRO.PA)

FAQ's for Geneuro SA (GNRO.PA)

According to Musaffa’s Shariah screening methodology, Geneuro SA (GNRO.PA) is currently classified as NOT HALAL as of September 2024. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.